POLBF (Poolbeg Pharma) Moat Score: 5/10 (As of Jun. 27, 2026)


What is Poolbeg Pharma Moat Score?

Poolbeg Pharma POLBF Moat Score is 5 as of Jun. 27, 2026. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Poolbeg Pharma ranks better than 96.72% on this metric.

Poolbeg Pharma has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Poolbeg Pharma has Narrow Moat: Poolbeg Pharma has a solid narrow moat due to its valuable intellectual property and ongoing R&D capabilities. However, its market share and brand strength are not robust enough for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Poolbeg Pharma might have Narrow Moat - Solid narrow moat.

Poolbeg Pharma  (OTCPK:POLBF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Poolbeg Pharma Moat Score Related Terms

POLBF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Poolbeg Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Poolbeg Pharma (POLBF) has a Moat Score of 5 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Poolbeg Pharma ranks #46 out of 1404 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Poolbeg Pharma's Moat Score too high?
Poolbeg Pharma's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Poolbeg Pharma's value of 5 is 150% above this industry median. Based on the distribution chart, Poolbeg Pharma ranks #46 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Poolbeg Pharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #46 out of 1404 companies for Moat Score. This places Poolbeg Pharma in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Poolbeg Pharma's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poolbeg Pharma's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Moat Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.